LambdaVision is pioneering the development of a protein-based artificial retina aimed at restoring vision for individuals suffering from retinal degenerative diseases such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The core technology leverages light-activated proteins, specifically bacteriorhodopsin, which mimics the natural light-absorbing properties of human photoreceptors. This innovative approach allows the artificial retina to activate the remaining neural cells in degenerated retinas, potentially offering a solution that surpasses the limitations of traditional electrode-based implants, which often result in low resolution and require external hardware.

The design of LambdaVision's artificial retina incorporates a sophisticated layer-by-layer production process, creating a structure that is dense enough to effectively absorb light. This structure consists of alternating layers of bacteriorhodopsin and a polymer, supported by a synthetic fiber membrane commonly used in medical applications. The final product is compact, roughly the size of a hole-punch, and flexible, making it suitable for implantation. Importantly, this technology is designed to function without the need for external power sources or bulky hardware, enhancing its practicality for patients with varying genetic backgrounds affected by RP.

United States

LambdaVision is developing the first protein-based artificial retina to restore meaningful vision for patients who are blind or have lost significant sight.

LambdaVision

Company Details